Novo Nordisk A/S (NOVO-B.CO)
Copenhagen - Copenhagen Real-time price. Currency in DKK
Add to watchlist
414.95+0.20 (+0.05%)
As of 1:29PM CET. Market open.
| Previous close | 414.75 |
| Open | 413.00 |
| Bid | 414.80 x 0 |
| Ask | 414.95 x 0 |
| Day's range | 412.05 - 416.20 |
| 52-week range | 331.70 - 467.90 |
| Volume | 505,073 |
| Avg. volume | 2,324,709 |
| Market cap | 960.601B |
| Beta (5Y monthly) | 0.36 |
| PE ratio (TTM) | 23.46 |
| EPS (TTM) | 17.69 |
| Earnings date | N/A |
| Forward dividend & yield | 8.60 (2.07%) |
| Ex-dividend date | 14 Aug 2020 |
| 1y target est | 326.96 |
- Zacks
Is Novo Nordisk (NVO) a Suitable Stock for Value Investors?
Let's see if Novo Nordisk A/S (NVO) stock is a good choice for value-oriented investors right now, or if investors subscribing to this methodology should look elsewhere for top picks.
- Zacks
Novo Nordisk's (NVO) Phase IIIb Study Meets Primary Endpoint
Novo Nordisk's (NVO) semaglutide 2.0 mg demonstrates superior reduction in HbA1c versus once-weekly semaglutide 1.0 mg in people with type II diabetes.
- Zacks
Gilead (GILD), Novo Nordisk Post Upbeat Data From NASH Study
Gilead (GILD) and Novo Nordisk present favorable outcomes from a mid-stage study in NASH patients.
© 2020 Verizon Media. All rights reserved.
